SCHEMBL30748952

SCHEMBL30748952

CCCNc1nc(CO)nc2c1C(C)(C)C(=O)N2c1ccc(N2CCOCC2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 5/20 0.37
RAD52 P43351 1/20 0.36
TLR7 Q9NYK1 1/20 0.35
FLT3 P36888 2/20 0.34
TYRO3 Q06418 2/20 0.34
MERTK Q12866 2/20 0.34
GAS6 Q14393 2/20 0.34
BRD4 O60885 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
TTK P33981 1/20 0.34
JAK3 P52333 1/20 0.34
AXL P30530 1/20 0.34
MAPT P10636 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749038 0.92 ADORA3 (0.39) SYKL3MBTL1JAK2JAK1TTK
SCHEMBL30748787 0.88 L3MBTL1 (0.36) SYKL3MBTL1JAK2JAK1TTK
SCHEMBL30749016 0.87 SYK (0.36) SYKL3MBTL1JAK2JAK1TTK
SCHEMBL30748933 0.87 SYK (0.40) SYKL3MBTL1JAK2JAK1TTK
SCHEMBL30748860 0.85 RAD52 (0.33) SYKRAD52TLR7FLT3TYRO3
SCHEMBL30748754 0.83 XDH (0.36) TLR7L3MBTL1MAPTSMN1; SMN2ALDH1A1
SCHEMBL30749058 0.78 ADORA3 (0.36) SYKL3MBTL1JAK2JAK1TTK
SCHEMBL30749139 0.76 MAOB (0.41) SYKFLT3JAK3SMN1; SMN2ALDH1A1
SCHEMBL30749040 0.74 TRPV1 (0.38) SYKJAK2MAPTALDH1A1RAB9A
SCHEMBL30748915 0.74 ADORA3 (0.40) L3MBTL1JAK2JAK1JAK3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT SYK 2316/4885RAD52 3673/4885TLR7 2372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.